The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the marketing authorisation of lutetium (177Lu) oxodotreotide for the treatment of unresectable or metastatic,...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vIEwMh
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Predictive Success Factors in Selective Upper Airway Stimulation. ORL J Otorhinolaryngol Relat Spec. 2017 Feb 24;79(1-2):121-128 Auth...
-
Abstract Background The introduction of aggressive chemo-radiotherapy regimens has improved overall survival in children with primitive ...
-
Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Me...
-
Abstract Desmoplastic small round cell tumor (DSCRT) is a rare malignancy most often seen in the abdomen or pelvis of young men. Unfortuna...
-
Abstract Nonmotor symptoms (NMS) have been described in several neurodegenerative diseases but have not been systematically evaluated in sp...
-
Article content meets expectations Minimal relevance to assigned subject matter. Article content fails to meet all requirements Not Rubric f...
-
Elementary school kids, on the other hand, can read, write, reason and think highly complex thoughts. Adele Faber and Elaine Mazlish, author...
-
by Mindaugas Paužuolis, Torsten Eich, Joachim Burman Background Natalizumab (NTZ) is a drug that has been widely used in the treatment of m...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου